Nordion.com is best viewed in Chrome, Firefox, Safari and Internet Explorer 10 and above.
Prevent. Diagnose. Treat.
Phase II Funding for Mo-99 Project
Nordion welcomes the United States Department of Energy’s (DOE) National Nuclear Security Administration Phase II funding for new, reliable source of molybdenum-99.
Nordion and Bruce Power sign long term contract to ensure global Cobalt-60 supply up to 2064.
REVISS Services UK Ltd. is now Nordion UK
We welcome Nordion UK, Registered as REVISS Services (UK) Ltd, to the Nordion family.
Supporting our Community
Hockey Fights Cancer – Nordion, as title sponsor, teams up with the Ottawa Senators and Ottawa Senators Foundation to raise funds for The Ottawa Hospital Foundation.
We are committed to keeping our employees, neighbours and the environment safe. Learn more about how we safeguard our community.
10-Year License Granted
We are proud to announce the decision from the Canadian Nuclear Safety Commission (CNSC) to renew the Nuclear Substance Processing Facility Operating License for Nordion’s Class 1B nuclear substance processing facility in Ottawa, Ontario.
Nordion and Bruce Power to create new, long-term supply of important cancer-treating isotope that will benefit healthcare patients around the world.
Nordion is one of the world’s foremost global health science organizations, exporting gamma technologies and medical isotopes all around the world.